CV

Cheemarla Vijaya Bhaskar Reddy

Active Director Director DIN 01484968
DIN 01484968 First appointment Nov 2003 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 2 historical roles
Total affiliations 5 Since Nov 2003
Shareholding value •••• Premium profile

About Cheemarla Vijaya Bhaskar Reddy

Data last updated:

Cheemarla Vijaya Bhaskar Reddy is a Director at Syntho Chirals Private Limited (since 2017), Director at Vaidhatru Pharma Private Limited (since 2019) and Designated Partner at Basl Biopharma Llp (since 2025). The companies operate in Pharma and Biotechnology. The 2 current companies with reported revenue have a combined latest revenue of ₹195 Cr; the largest is Syntho Chirals Private Limited at ₹162 Cr (FY 2024). Earlier, Cheemarla Vijaya Bhaskar Reddy was a Director at Gpr Life Sciences Private Limited (2021–2023) and Managing Director at Prathiraj Space Cam Solutions Private Limited (from 2003).

DIN 01484968
Primary Designation Director
Industry Pharma
First Appointment 27 Nov 2003
Oldest Company Age 22 yrs
Largest company Syntho Chirals Private Limited · ₹162 Cr (FY 2024)
Combined revenue ₹195 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Syntho Chirals Private Limited U24239TG2004PTC043066
Director22 Jun 20172004₹162 Cr (FY 2024)Active
Vaidhatru Pharma Private Limited U24232TG2007PTC055812
Director20 Feb 20192007₹32.48 Cr (FY 2024)Active
Designated Partner25 Feb 20252025Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Gpr Life Sciences Private Limited U24232TG2011PTC126431
Director23 Aug 20212011₹27.5 Lakh (FY 2025)Active
Managing Director27 Nov 20032003Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Vaidhatru Pharma Private Limited
Syntho Chirals Private Limited
Prathiraj Space Cam Solutions Private Limited
Basl Biopharma Llp
Premium access

Shareholding and investment profile for Cheemarla Vijaya Bhaskar Reddy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cheemarla Vijaya Bhaskar Reddy

Cheemarla Vijaya Bhaskar Reddy currently holds 3 directorships: Syntho Chirals Private Limited (Director, since 22 Jun 2017, revenue ₹162 Cr (FY 2024)); Vaidhatru Pharma Private Limited (Director, since 20 Feb 2019, revenue ₹32.48 Cr (FY 2024)); Basl Biopharma Llp (Designated Partner, since 25 Feb 2025).

Cheemarla Vijaya Bhaskar Reddy was first appointed on 27 Nov 2003 as Managing Director at Prathiraj Space Cam Solutions Private Limited. The most recent appointment on record is 25 Feb 2025 at Basl Biopharma Llp.

The 2 current companies of Cheemarla Vijaya Bhaskar Reddy that report revenue have a combined latest revenue of ₹195 Cr: Syntho Chirals Private Limited ₹162 Cr (FY 2024); Vaidhatru Pharma Private Limited ₹32.48 Cr (FY 2024).

Cheemarla Vijaya Bhaskar Reddy held 2 earlier board appointments: Gpr Life Sciences Private Limited (Director, 23 Aug 2021 to 30 Mar 2023); Prathiraj Space Cam Solutions Private Limited (Managing Director, from 27 Nov 2003).

The current boards of Cheemarla Vijaya Bhaskar Reddy's companies include Anitha Reddy Ragi (Syntho Chirals Private Limited), Aruna Reddy Ragi (Syntho Chirals Private Limited), Linga Reddy Ragi (Syntho Chirals Private Limited), Ragi Bhuvanesh Reddy (Syntho Chirals Private Limited), Sai Kiran Reddy Ragi (Syntho Chirals Private Limited), Sridhar Reddy Ragi (Syntho Chirals Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available